Suppr超能文献

替格列汀的化学、分析和药理学研究进展:一种新型的 DPP-4 抑制剂。

Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor.

机构信息

Quality Assurance, School of Pharmacy and Technology Management, NMIMS, Shirpur, India.

Pharmacology, School of Pharmacy and Technology Management, NMIMS, Shirpur, India.

出版信息

Mini Rev Med Chem. 2020;20(12):1091-1100. doi: 10.2174/1389557520666200228144148.

Abstract

This article provides comprehensive and collective facts about teneligliptin. Teneligliptin is a dipeptide peptidase-4 (DPP-4) inhibitor that belongs to the third generation, used in the management of type 2 diabetes. It inhibits human DPP-4 enzyme activity. This drug falls under class 3; it interacts with S1, S2, and S2E extensive sub-sites. Teneligliptin and its metabolites are mainly determined in the human plasma matrix by hyphenated chromatographic methods. These developed methods could be foreseen for their clinical applications. Moreover, the stress degradation studies of Teneligliptin under different stress conditions provide an insight into degradation pathways and help in the elucidation of the structure of the degradation products by liquid mass spectroscopy. These methods are also used for routine quality control analysis of teneligliptin in pharmaceutical dosage forms.

摘要

本文提供了关于替格列汀的全面综合事实。替格列汀是一种属于第三代的二肽基肽酶-4(DPP-4)抑制剂,用于 2 型糖尿病的治疗。它抑制人 DPP-4 酶的活性。该药物属于 3 类,与 S1、S2 和 S2E 广泛亚位点相互作用。替格列汀及其代谢物主要通过键合色谱法在人血浆基质中测定。这些开发的方法有望用于临床应用。此外,在不同的应激条件下替格列汀的应激降解研究为降解途径提供了深入了解,并通过液相质谱帮助阐明了降解产物的结构。这些方法也用于药物制剂中替格列汀的常规质量控制分析。

相似文献

2
Teneligliptin for the treatment of type 2 diabetes.替奈利肽治疗2型糖尿病。
Drugs Today (Barc). 2013 Oct;49(10):615-29. doi: 10.1358/dot.2013.49.10.2035882.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验